Bright Minds Biosciences

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every five (5) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 3,772,071 common shares.

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “Common Shares”) on a five (5) to one (1) basis (the “Consolidation”).

Bright Minds Announces Effective Date of Share Consolidation

VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it intends to consolidate its common shares (the “Common Shares”) on a five (5) to one (1) basis (the “Consolidation”). The Consolidation has been approved by the Company's board of directors in accordance with the Articles of the Company.

Bright Minds Announces Proposed Share Consolidation

Genprex

Heliogen

Inovio Pharmaceuticals

mCloud Technologies Corp

National CineMedia

NeuroBo Pharmaceuticals Inc

Oncternal Therapeutics Inc

Predictive Oncology Inc

Vascular Biogenics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 10 Under $1 To Watch This Week

-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B -- -- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds --

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" —

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization –

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases

Bright Minds Biosciences Announces Non-Executive Director Appointment

VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company's board of directors and audit committee, the Company no longer complies with NASDAQ's independent director and audit committee requirements as set forth in Listing Rule 5605.

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated January 26, 2023, notifying the Company that due to thirty consecutive business days of closing bid prices for the common shares in the capital of the Company (the “Shares”) being below US$1.00 per Share, Bright Minds is not compliant with the minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2).

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board.

Bright Minds Biosciences Announces Resignation of Board Member

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Announces Non-Brokered Private Placement

-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022. The Company also announces that Dr. Revati Shreeniwas' engagement with Bright Minds as Chief Medical Officer has been terminated.

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Today's continued rally across equity markets is providing a bullish lift to many investors who have had their sentiment beat down to a great degree this year. While broad-based, certain sectors of the market are rallying more than others today.

What Is Going on With Bright Minds (DRUG) Stock Today?

Gevo

Alaunos Therapeutics

How to make money with penny stocks during a market crash The post Making Money With Penny Stocks When the Market Crashes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Making Money With Penny Stocks When the Market Crashes

Applied Optoelectronics

India Globalization Capital

Penny stocks to buy? High volume has placed them on the watch list in the stock market today.

4 High Volume Penny Stocks To Watch While The Stock Market Is Down

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Ampio Pharmaceuticals Inc

New Age Beverages

Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?

Which Strategies Are You Using With Penny Stocks in September?

Ardelyx

ironSource Ltd

MannKind

Are these penny stocks to buy now or avoid in September? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 To Watch This Month

In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

First High-School Education Group Co

Luokung Technology Corp

What to know about buying penny stocks today The post Hot Penny Stocks to Watch in the First Week of September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch in the First Week of September

News for Bright Minds Biosciences Stock (DRUG)